Navigation Links
Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
Date:2/26/2008

PRINCETON, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the completion of recruitment in the company's multi-center Phase 2a clinical study of PS433540 (DARA), the company's lead internal product candidate. The objective of the Phase 2a randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of 200 and 500 mg of PS433540 in subjects with Stage I and Stage II hypertension.

"We have made good progress advancing DARA's clinical development. Not only did we initiate this Phase 2a study approximately six months ahead of our original clinical development timeline, but we have now completed enrollment in the study with the expectation of reporting results in the second quarter of 2008," said Les Browne, Ph.D., Pharmacopeia's President and Chief Executive Officer. "As this is the first PS433540 study to include hypertensive patients, we are pleased to have the opportunity to demonstrate that DARA can effectively lower blood pressure in this patient population."

Results from Phase 1 studies of PS433540 in normal subjects have indicated that the compound was well tolerated at all doses up to and including 1,000 mg a day for 14 days. Several studies including the multiple ascending dose (MAD) and angiotensin II challenge studies have shown that PS433540 appears to have a pharmacokinetic profile consistent with once-daily oral administration. In the angiotensin challenge study, 250 and 500 mg of PS433540 fully blocked the increase in blood pressure induced by administration of angiotensin II (AII) to healthy volunteers at least as well as 300 mg of irbesartan, the t
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
3. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
4. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
5. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
6. Pharmacopeia Announces Third Quarter 2007 Financial Results
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
9. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
(Date:5/17/2013)... Sinovac Biotech Ltd. (Nasdaq: SVA ), a leading ... announced that it will release its unaudited financial results for ... Tuesday, May 28, 2013.  The Company will host a conference ... (May 28, 2013 at 8:00 p.m. China Standard Time) to ... recent corporate developments. To access the conference call, ...
Breaking Medicine Technology:PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
(Date:5/18/2013)... 18, 2013 The product liability attorneys at ... on behalf of consumers nationwide who have sustained serious tendon ... shoes. These cases are all part of MDL 2308 and ... lawsuits will be heard in the U.S. District Court ... Wright & Schulte, LLC specializes in defending the rights of ...
(Date:5/17/2013)... J. Schultz, D.D.S., is making the Laser Assisted New Attachment ... of San Juan Capistrano. The laser surgery disintegrates up ... a scalpel to cut the tissue away. The periodontist ... wavelengths to target the diseased tissue and bacteria while leaving ... in every hundred dental professionals is trained and authorized to ...
(Date:5/17/2013)... May 17, 2013 Stryker hip lawsuit ... year’s Rejuvenate and ABG II Modular-Neck Hip Stem recall continue ... LLP reports. According to court documents, a Case Management ... May 15th, at which time the Court, among other things, ... the litigation must submit Fact Sheets to Defendant and Liaison ...
(Date:5/17/2013)... 17, 2013 Charlotte’s top professional athletes ... with children served by the Muscular Dystrophy Association at ... Tuesday, May 21 at Bank of America Stadium from ... unique social event that pairs top professional athletes and ... an “MDA Buddy” (a local child living with a ...
(Date:5/17/2013)... 2013 Parker Waichman LLP , ... of victims injured by defective medical devices, notes that ... in a May 16, 2013, statement that ... ceramic-on-metal hip replacement products; specifically, the metal liners in ... Hip System will no longer be available worldwide after ...
Breaking Medicine News(10 mins):Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:San Clemente, CA Periodontist, Dr. Allen J. Schultz, Now Provides Laser Gum Disease Treatment to Southern Orange County Periodontal Disease Patients 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 3Health News:MDA Hosts Annual Charlotte Muscle Team Event 2Health News:MDA Hosts Annual Charlotte Muscle Team Event 3Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 3
... continued to pay for sex despite having steady partners, according to ... to visiting prostitutes recently while 27 percent admitted that it was ... paying for sex were in a concurrent relationship," said Dr Tamsin ... sex while at home or abroad, but used condoms in most ...
... infamous for food poisoning that kills hundreds of ... into and multiply inside macrophages, the very immune ... and destroy invading microbes. ,Just how ... to prey complicit in promoting infection, has seemed ...
... the University of Michigan Health System finds that treating ... alpha blocker has many benefits// and can even allow ... the US, the disease affects 13 percent of men ... by minimally invasive surgery, but research suggests that medicines ...
... of public health interventions can cost hundreds of lives, especially ... if the science is good, we should act before the ... required before new interventions are implemented. But in 2003, the ... parachutes to show that situations still exist where such trials ...
... Loma Linda University (LLU) shows that adding just a handful ... oxidation of blood lipids// , thus helping reduce the risk ... in part due to the pecan’s significant content of vitamin ... of phytochemicals that can have a unique effect on the ...
... stress syndrome, better known as shin splints, in distance runners ... in Messina, Italy. ,According to the study, medial ... injuries that may be found in athletes and accounts for ... ,For the study, high-resolution CT of both tibiae (shin bones) ...
Cached Medicine News:Health News:An Infectious Agent of Deception, Exposed Through Proteomics 2Health News:Drugs May Help Urinary Disease 2Health News:Antioxidant-Rich Pecans Protect Against Unhealthy Oxidation in the Body 2
Rubella IgG II ELISA....
The Urine Legionella Antigen ELISA kit detects the presence of Legionella pneumophila serogroup1 antigen in urine....
Mumps IgG ELISA....
Measles IgG ELISA....
Medicine Products: